Engineers Gate Manager LP Prothena Corp Public LTD CO Transaction History

Engineers Gate Manager LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$32.31 - $52.32 $812,241 - $1.32 Million	25,139 Added 220.83%	36,523 $1.33 Million
Q3 2023 Nov 14, 2023	BUY	$47.3 - $70.6 $363,405 - $542,419	7,683 Added 207.59%	11,384 $549,000
Q2 2023 Aug 14, 2023	SELL	$48.26 - $78.59 $517,347 - $842,484	-10,720 Reduced 74.34%	3,701 $252,000
Q1 2023 May 15, 2023	BUY	$46.97 - $58.27 $483,133 - $599,365	10,286 Added 248.75%	14,421 $698,000
Q4 2022 Feb 14, 2023	BUY	$52.05 - $65.0 $215,226 - $268,775	4,135 New	4,135 $249,000
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $499,878 - $879,240	-21,992 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$30.27 - $49.22 $665,697 - $1.08 Million	21,992 New	21,992 $804,000
Q4 2021 Feb 14, 2022	SELL	$42.11 - $73.26 $440,849 - $766,958	-10,469 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$48.2 - $78.89 $16,436 - $26,901	-341 Reduced 3.15%	10,469 $746,000
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $233,820 - $623,196	10,810 New	10,810 $556,000

186

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $726M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.